GSK Offers $28M To Settle Suits Over Defective Paxil
GlaxoSmithKline PLC has agreed to pay $28 million to settle two proposed class actions over claims that the company's Puerto Rico plant produced defective versions of the company's antidepressant Paxil CR...To view the full article, register now.
Already a subscriber? Click here to view full article